Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Liu, Yang ^{[1
]}

Yan, Zhiling ^{[2
]}

Wu, Qingyun ^{[2
]}

Chen, Chong ^{[2
]}

Cao, Jiang ^{[2
]}

Li, Zhenyu ^{[2
]}

Xu, Kailin ^{[2
]}

机构：

[1] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[2] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-029

引用

页码：S49 / S49

页数：1

共 50 条

[1] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
Ding, Hong
Wu, Yu
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
[2] CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
Hakan, Goker
Engin, Kelkitli
Elifcan, Karakulak Aladag
Haluk, Demiroglu
Mehmet, Turgut
Suman, Kambhampati
Maxwell, Krem
FRONTIERS IN MEDICINE, 2024, 11
[3] Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
Wu, Weijia
Ding, Shuyi
Zhang, Mingming
Zhou, Yuping
Sun, Xueshan
Zhao, Zixuan
Yang, Yi
Hu, Yongxian
Dong, Hengjin
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 701 - 709
[4] Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fandrei, David
Seiffert, Sabine
Rade, Michael
Rieprecht, Susanne
Gagelmann, Nico
Born, Patrick
Wiemers, Thomas
Weidner, Heike
Kreuz, Markus
Schassberger, Tamara
Kossmann, Jannik
Mangold, Marlene
Fuerst, Daniel
Fischer, Luise
Baber, Ronny
Heyn, Simone
Wang, Song Yau
Bach, Enrica
Hoffmann, Sandra
Metzeler, Klaus H.
Herling, Marco
Jentzsch, Madlen
Franke, Georg-Nikolaus
Koehl, Ulrike
Friedrich, Maik
Boldt, Andreas
Reiche, Kristin
Platzbecker, Uwe
Vucinic, Vladan
Merz, Maximilian
BLOOD CANCER DISCOVERY, 2025, 6 (01): : 38 - 54
[5] Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Ma, Ruixue
Zhang, Qi
Liu, Yang
Li, Hujun
Chen, Huimin
Zhang, Qianqian
Qiao, Jianlin
Qi, Kunming
Shen, Guifang
Sun, Cai
Song, Xuguang
Cao, Jiang
Cheng, Hai
Zhu, Feng
Yan, Zhiling
Sang, Wei
Li, Depeng
Sun, Haiying
Zheng, Junnian
Li, Zhenyu
Xu, Kailin
Chen, Wei
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
[6] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Gill, Sarvarinder Kaur
Biran, Noa
Phull, Pooja
Vesole, David H.
Siegel, David S.
Parmar, Harsh
BLOOD, 2023, 142
[7] Bispecific Antibodies Improve Outcomes in Patients With Relapsed or Refractory Multiple Myeloma After Car-T Cell Therapy
Merz, Maximilan
Dima, Danai
Hashmi, Hamza
Mueller, Fabian
Ahmed, Nausheen
Rathje, Kristin
Davis, James
Holderried, Tobias
Vucinik, Vladan
Kharbouti, Soraya
Ayuk, Francis
Stoelzel, Friedrich
Schub, Natalie
Schmitz, Friederike
Shune, Leyla
Khouri, Jack
Anwer, Faiz
McGuirk, Joseph
Teichert, Marcel
von Tresckow, Bastian
Kroeger, Nicolaus
Pabst, Thomas
Abdallah, Al-Ola
Gagelmann, Nico
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S73 - S74
[8] Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
An, Jing
Zhao, Jie
Zou, Ping
Zhang, Yicheng
Wei, Junni
Tian, Weiwei
Wei, Jia
CANCER MEDICINE, 2024, 13 (12):
[9] Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Min, Chao
Zhong, Xiong
Cui, Yue
Zhang, Hanfu
Wang, Qingming
FRONTIERS IN PHARMACOLOGY, 2025, 16
[10] CAR T-cell therapy for relapsed or refractory multiple myeloma
Stirrups, Robert
LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297

← 1 2 3 4 5 →